Institute for Clinical and Experimental Medicine, Department of Experimental Endocrinology, Prague, Czechia.
Institute for Clinical and Experimental Medicine, Department of Clinical and Transplant Pathology, Prague, Czechia.
Kidney Blood Press Res. 2021;46(2):245-249. doi: 10.1159/000513710. Epub 2021 Mar 23.
Preclinical studies suggested that pharmacological inhibition of the renin-angiotensin-aldosterone system (RAAS) by ACE inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) may increase local angiotensin-converting enzyme 2 (ACE2) expression.
In this study, we evaluated the effect of ACEi or ARB treatment on expression of ACE2, ACE, and AGTR1 in 3-month protocol kidney allograft biopsies of stable patients using RT-qPCR (n = 48). Protein ACE2 expression was assessed using immunohistochemistry from paraffin sections.
The therapy with RAAS blockers was not associated with increased ACE2, ACE, or ATGR1 expression in kidney allografts and also ACE2 protein immunohistochemistry did not reveal differences among groups.
ACEis or ARBs in kidney transplant recipients do not affect local ACE2 expression. This observation supports long-term RAAS treatment in kidney transplant recipients, despite acute complications such as COVID-19 where ACE2 serves as the entry protein for infection.
临床前研究表明，血管紧张素转换酶抑制剂（ACEi）或血管紧张素 II 受体阻滞剂（ARB）通过抑制肾素-血管紧张素-醛固酮系统（RAAS）可能会增加局部血管紧张素转换酶 2（ACE2）的表达。
本研究采用 RT-qPCR （n=48）评估了 3 个月方案中肾移植受者稳定期 RAAS 阻滞剂治疗对 ACE2、ACE 和 AGTR1 表达的影响。使用免疫组化从石蜡切片评估 ACE2 蛋白的表达。
RAAS 阻滞剂治疗与肾移植中 ACE2、ACE 或 ATGR1 表达增加无关，ACE2 蛋白免疫组化也未显示各组之间存在差异。
肾移植受者中 ACEi 或 ARB 不影响局部 ACE2 表达。这一观察结果支持肾移植受者长期 RAAS 治疗，尽管 ACE2 是感染的进入蛋白，但会出现 COVID-19 等急性并发症。
